文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

早期糖皮质激素治疗非HIV成人肺孢子菌肺炎与更好的结局无关

Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are Not Associated With Better Outcome.
PubMed 文献 · Chest · 2018-04-26
一句话结论回顾性队列显示,非HIV成人肺孢子菌肺炎早期使用糖皮质激素与第5天SOFA呼吸评分改善更少相关,未改善呼吸结局。

该回顾性队列纳入2006至2016年Mayo Clinic收治的323例非HIV肺孢子菌肺炎阳性住院患者,其中早期(48小时内)使用激素者258例,未使用激素者65例。采用多变量logistic回归和倾向匹配分析比较第5天SOFA呼吸评分(SOFAresp)较基线的变化。严重度校正回归和倾向匹配分析均发现,早期使用激素与第5天SOFAresp改善更少相关(P=0.001和P=0.017),但两组第5天SOFAresp至少改善1分的比值无差异(校正OR 0.76,95%CI 0.24-2.28;P=0.61)。30天总死亡率为22.9%(95%CI 18.2-27.4),两组在死亡率、住院时间、ICU入住或机械通气需求方面均无差异。

要点

  • 非HIV成人肺孢子菌肺炎早期(48小时内)使用激素与第5天SOFAresp改善更少相关(严重度校正回归P=0.001,倾向匹配P=0.017)。
  • 两组第5天SOFAresp至少改善1分的比值无差异(校正OR 0.76,95%CI 0.24-2.28;P=0.61)。
  • 30天总死亡率为22.9%(95%CI 18.2-27.4),早期激素组与未用激素组死亡率无差异。
  • 两组在住院时间、ICU入住率或机械通气需求方面均无差异。
  • 在非HIV肺孢子菌肺炎患者中,早期加用糖皮质激素未显示呼吸结局获益。

适用人群与场景

  • 非HIV、住院、肺孢子菌肺炎阳性的成人患者,来自2006至2016年Mayo Clinic收治人群。

研究设计与关键结果

  • 研究类型为回顾性队列,纳入323例非HIV肺孢子菌肺炎阳性住院患者,早期激素组258例,未用激素组65例。
  • 中位年龄65岁(四分位距53-73),男性占63%,白人占92%。
  • 严重度校正回归和倾向匹配分析显示,早期使用激素与第5天SOFAresp改善更少相关(P=0.001和P=0.017)。
  • 第5天SOFAresp至少改善1分的比值两组无差异(校正OR 0.76,95%CI 0.24-2.28;P=0.61)。
  • 30天总死亡率为22.9%(95%CI 18.2-27.4)。
  • 两组死亡率、住院时间、ICU入住或机械通气需求均无差异。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于非HIV成人肺孢子菌肺炎住院患者,早期(48小时内)加用糖皮质激素未显示呼吸结局获益,决策时应权衡个体情况。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Evidence supporting adjunctive corticosteroids during the treatment of Pneumocystis jirovecii pneumonia (PcP) in adults without HIV is minimal and controversial.

METHODS: This retrospective cohort study included P jirovecii pneumonia-positive, hospitalized patients without HIV admitted to the Mayo Clinic from 2006 to 2016. Change from baseline in the respiratory component of the Sequential Organ Failure Assessment score (SOFAresp) at day 5 was compared between early (within 48 h) steroid recipients and nonrecipients by using multivariable logistic regression and in a propensity-matched analysis.

RESULTS: Among the 323 included patients (early steroids, n = 258; no steroids, n = 65), the median (interquartile range) age was 65 (53, 73) years, 63% were male, and 92% were white. Severity-adjusted regression and propensity-matched analyses found that early administration of steroids was associated with less improvement in SOFAresp at day 5 compared with no steroids (P = .001 and P = .017, respectively). No differences were observed in the odds of having at least a one-point improvement in SOFAresp at day 5 compared with baseline between groups (adjusted OR, 0.76 [95% CI, 0.24-2.28]; P = .61). Overall 30-day mortality was 22.9% (95% CI, 18.2-27.4). No differences in mortality, length of stay, admission to the ICU, or need for mechanical ventilation were found between early steroid recipients and nonrecipients.

CONCLUSIONS: The addition of early corticosteroids to anti-Pneumocystis therapy in patients without HIV was not associated with improved respiratory outcomes.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Wieruszewski PM, Barreto JN, Frazee E, et al. Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are Not Associated With Better Outcome. Chest. 2018. PMID: 29705221. doi:10.1016/j.chest.2018.04.026

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。